Tuulikki Sokka1. 1. Jyväskylä Central Hospital, Jyväskylä 40620, Finland. tuulikki.sokka@ksshp.fi
Abstract
PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is recognized as a disease with a natural history of severe long-term outcomes, which appear to be improving at this time, as reported from many clinics. RECENT FINDINGS: Improved outcomes of many long-term consequences of inflammation such as joint deformity, functional declines, work disability, and early death have been reported in recent years. SUMMARY: Therapies for RA are assessed in randomized clinical trials and in clinical care primarily according to measures of inflammatory activity, which may change considerably over days, weeks, and months. In usual clinical care, long-term consequences of the disease, which often require years of observation, can also be assessed. Data in published reports of both clinical trials and clinical care continue to include only a minority of all patients with RA. Further efforts are needed to promote collection of quantitative data in all patients with RA, at all visits in all clinical settings, to facilitate 'tight control' and better outcomes for all patients with RA.
PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is recognized as a disease with a natural history of severe long-term outcomes, which appear to be improving at this time, as reported from many clinics. RECENT FINDINGS: Improved outcomes of many long-term consequences of inflammation such as joint deformity, functional declines, work disability, and early death have been reported in recent years. SUMMARY: Therapies for RA are assessed in randomized clinical trials and in clinical care primarily according to measures of inflammatory activity, which may change considerably over days, weeks, and months. In usual clinical care, long-term consequences of the disease, which often require years of observation, can also be assessed. Data in published reports of both clinical trials and clinical care continue to include only a minority of all patients with RA. Further efforts are needed to promote collection of quantitative data in all patients with RA, at all visits in all clinical settings, to facilitate 'tight control' and better outcomes for all patients with RA.
Authors: M Das; J Lu; M Joseph; R Aggarwal; S Kanji; B K McMichael; B S Lee; S Agarwal; A Ray-Chaudhury; O H Iwenofu; P Kuppusamy; V J Pompili; M K Jain; H Das Journal: Curr Mol Med Date: 2012-02 Impact factor: 2.222
Authors: Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung Journal: Clin Rev Allergy Immunol Date: 2014-10 Impact factor: 8.667
Authors: Marie Hudson; Sasha Bernatsky; Ines Colmegna; Maximilien Lora; Tomi Pastinen; Kathleen Klein Oros; Celia M T Greenwood Journal: Epigenetics Date: 2017-04-07 Impact factor: 4.528
Authors: P C Rodríguez; D M Prada; E Moreno; L E Aira; C Molinero; A M López; J A Gómez; I M Hernández; J P Martínez; Y Reyes; J M Milera; M V Hernández; R Torres; Y Avila; Y Barrese; C Viada; E Montero; P Hernández Journal: Clin Exp Immunol Date: 2017-11-16 Impact factor: 4.330
Authors: Ann M Taylor; Kristine Phillips; Kushang V Patel; Dennis C Turk; Robert H Dworkin; Dorcas Beaton; Daniel J Clauw; Monique A M Gignac; John D Markman; David A Williams; Shay Bujanover; Laurie B Burke; Daniel B Carr; Ernest H Choy; Philip G Conaghan; Penney Cowan; John T Farrar; Roy Freeman; Jennifer Gewandter; Ian Gilron; Veeraindar Goli; Tony D Gover; J David Haddox; Robert D Kerns; Ernest A Kopecky; David A Lee; Richard Malamut; Philip Mease; Bob A Rappaport; Lee S Simon; Jasvinder A Singh; Shannon M Smith; Vibeke Strand; Peter Tugwell; Gertrude F Vanhove; Christin Veasley; Gary A Walco; Ajay D Wasan; James Witter Journal: Pain Date: 2016-09 Impact factor: 7.926
Authors: Femke H M Prince; Vivian P Bykerk; Nancy A Shadick; Bing Lu; Jing Cui; Michelle Frits; Christine K Iannaccone; Michael E Weinblatt; Daniel H Solomon Journal: Arthritis Res Ther Date: 2012-03-19 Impact factor: 5.156